Wild poliovirus type 2 (WPV2) was formally declared eradicated in September 2015 \[[@r1]\]. In April 2016, there was a globally coordinated replacement of trivalent oral poliovirus vaccine (tOPV) with bivalent OPV (bOPV) which lacks the type-2 poliovirus vaccine strain \[[@r2]\]. In July 2016, the Global Action Plan III (GAP III) \[[@r3]\], a protocol specifically designed to minimise the risk for re-emergence of type-2 poliovirus (PV2) from laboratory sources, restricted work and storage of PV2, and any materials that potentially contained this virus to annually certified 'essential' poliovirus laboratories that meet strict containment and biosafety standards. However, PV2 may re-emerge during this time from an alternative source for which there is no corresponding GAP III protocol, namely, prolonged infections with OPV type 2 (OPV2) in primary immune deficiency patients (PIDs) especially in closed hospital settings.

We present identification by chance of a prolonged PV2 infection in a primary immune deficient child in Israel during the global transition to a PV2-free world. This report serves to raise public health awareness of the implications for re-emergence of PV2.

Primary immune deficient case with a prolonged poliovirus infection
===================================================================

A young non-Israeli child received a routine dose of tOPV at 2 months of age in the country of residence. Because of failing to thrive and frequent infections, the child was hospitalised at 5 months of age in Israel with a suspected diagnosis of severe immune deficiency. Fluorescence-activated cell sorting (FACS) analysis confirmed T-B-NK + immune phenotype, and genetic evaluation revealed a homozygote DNA cross-link repair 1C (*DCLRE1C*) gene mutation, leading to a final diagnosis of severe combined immune deficiency (SCID). The child was placed in reverse isolation, was started on antibiotic prophylaxis and received intravenous immunoglobulin (IVIG) once a month. At 8 months of age, the child received a haploidentical haematopoietic stem cell transplantation (HSCT). Microsatellite analysis 8 months post-bone marrow transplant (BMT) to evaluate engraftment suggested transplant failure. Currently, the child is awaiting a second transplantation.

After confirmation of SCID and before the HSCT, a stool sample was sent for viral diagnosis of transient diarrhoea to the National Poliovirus and Enterovirus Laboratory. It was positive for enterovirus by real-time reverse transcription-polymerase chain reaction (RT-PCR) and the virus had a cytopathic effect (CPE) on L20B cells suggesting poliovirus.

Viral protein 1 (VP1) sequence typing \[[@r4],[@r5]\] identified the enterovirus as a type-2 vaccine derived poliovirus (VDPV2) with nine nucleotide (nt) and five amino acid substitutions. Single nt misincorporations accumulate at a rate of ca 1% per year as polioviruses replicate during person-to-person transmission (circulating VDPV: cVDPV) or persistent infections in immune deficient individuals (immunodeficiency-related VDPV: iVDPV) \[[@r6]\]. Nine nt substitutions are consistent with prolonged infection after receiving the tOPV dose. Attenuation of neurovirulence in OPV2 is conferred by nt 481 in the 5' untranslated region (UTR) and the nts that encode amino acid 143 in VP1 \[[@r7]\]. Both nt 481 and amino acid 143 had reverted to wild type. It is important to stress that at no stage did the patient exhibit symptoms of paralytic poliomyelitis (acute flaccid paralysis: AFP), thus this situation would have been missed by classic AFP surveillance. Oral use of gamma globulin product did not yet clear this prolonged poliovirus infection.

Measures to prevent onward transmission and follow-up
=====================================================

Upon notification of the poliovirus infection, the child was transferred to a contact isolation room requiring entrance with disposable gown and use of gloves and stools are monitored monthly. All visitors receive an explanation of the child\'s condition and instructions on hand hygiene.

Eight stool samples taken approximately once every month, including one from this August, have remained VDPV2-positive and the virus has continued to evolve. Important information can be derived from the temporal pattern of nt and inferred amino acid substitutions that persist or are transitory during early stages in the establishment of persistence. Such changes are highlighted in the [Table](#t1){ref-type="table"} in yellow and green, respectively for isolates from our SCID patient.

###### Nucleotide and amino acid changes in viral protein 1 over time in immunodeficiency-related vaccine-derived poliovirus isolated from the stools of a severe combined immune deficiency patient, Israel, October 2015--August 2016

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sabin 2 sequence               Immunodeficiency-related vaccine-derived poliovirus type 2 isolate number\                                                                             
                                 Approximate number of days after last trivalent oral poliovirus vaccine                                                                                
  ------------------------------ ---------------------------------------------------------------------------- ------------------------- ------- ------- ------- ------- ------- ------- -------
  **Position**                   **Nt**                                                                       **Nt substitutions^a^**                                                   

  10                             G                                                                            None                      None    None    None    None    None    None    T

  26                             C                                                                            T                         T       T       T       T       T       T       T

  40                             A                                                                            G                         G       G       G       G       G       G       G

  44                             A                                                                            None                      None    None    G       G       G       G       G

  55                             G                                                                            None                      None    None    None    R       None    None    None

  81                             G                                                                            None                      None    None    A       R       R       None    None

  103                            C                                                                            None                      None    None    None    None    None    T       None

  117                            G                                                                            A                         A       A       A       A       A       A       A

  288                                                                                                         None                      None    None    None    None    None    None    R

  308                            G                                                                            A                         A       A       A       A       A       A       A

  364                            C                                                                            T                         T       T       T       T       T       T       T

  405                            T                                                                            None                      None    None    None    None    Y       None    None

  **428^b^**                     **T**                                                                        **C**                     **C**   **C**   **C**   **C**   **C**   **C**   **C**

  459                            A                                                                            None                      None    None    None    None    R       G       G

  486                            C                                                                            None                      None    None    T       T       T       T       T

  501                            T                                                                            None                      None    None    None    None    Y       None    None

  516                            C                                                                            T                         T       T       T       T       T       T       T

  540                            C                                                                            None                      None    None    None    Y       Y       None    None

  600                            A                                                                            None                      None    None    None    None    W       None    None

  660                            A                                                                            None                      None    None    None    None    None    R       None

  769                            A                                                                            G                         G       G       G       G       G       G       G

  849                            T                                                                            A                         A       A       A       A       A       A       A

  **Total Nt changes**           9                                                                            9                         9       12      14      17      14      14      

  **Position**                   **AA**\                                                                      **AA substitutions**\                                                     
                                 **(codon)**                                                                  **(codon^a^)**                                                            

  4                              D\                                                                           None                      None    None    None    None    None    None    Y\
                                 (GAC)                                                                                                                                                  (TAC)

  9                              A\                                                                           V\                        V\      V\      V\      V\      V\      V\      V\
                                 (GCC)                                                                        (GTC)                     (GTC)   (GTC)   (GTC)   (GTC)   (GTC)   (GTC)   (GTC)

  14                             T\                                                                           A\                        A\      A\      A\      A\      A\      A\      A\
                                 (ACT)                                                                        (GCT)                     (GCT)   (GCT)   (GCT)   (GCT)   (GCT)   (GCT)   (GCT)

  15                             K\                                                                           None                      None    None    R\      R\      R\      R\      R\
                                 (AAA)                                                                                                                  (AGA)   (AGA)   (AGA)   (AGA)   (AGA)

  19                             V\                                                                           None                      None    None    None    I/V\    None    None    None
                                 (GTT)                                                                                                                          (RTT)                   

  35                             P\                                                                           None                      None    None    None    None    None    S\      None
                                 (CCA)                                                                                                                                          (TCA)   

  103                            R\                                                                           K\                        K\      K\      K\      K\      K\      K\      K\
                                 (AGA)                                                                        (AAA)                     (AAA)   (AAA)   (AAA)   (AAA)   (AAA)   (AAA)   (AAA)

  **143^b^**                     I\                                                                           T\                        T\      T\      T\      T\      T\      T\      T\
                                 (ATT)                                                                        (ACT)                     (ACT)   (ACT)   (ACT)   (ACT)   (ACT)   (ACT)   (ACT)

  257                            I\                                                                           V\                        V\      V\      V\      V\      V\      V\      V\
                                 (ATC)                                                                        (GTC)                     (GTC)   (GTC)   (GTC)   (GTC)   (GTC)   (GTC)   (GTC)

  **Total amino acid changes**   5                                                                            5                         5       6       7       6       7       7       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AA: amino acid; Nt: nucleotide.

Cells in green represent transitory nt or inferred amino acid substitutions while cells in yellow indicate substitutions that persist in all subsequent isolates. When a mutation is first detected in the latest isolate obtained, the cell is not shaded as it is remains to be seen whether this mutation will be found in further isolates.

^a^ R = A and G; Y = C and T; W = A and T.

^b^ Neurovirulence attenuation site.

The patient will continue to be monitored monthly until cessation of infection is documented \[[@r8]\] by two successive VDPV2 monthly samples. Prolonged infection either ceases spontaneously, in some cases after BMT, or becomes persistently established \[[@r9]\]. The patient can remain asymptomatic for years \[[@r9],[@r10]\], develop poliomyelitis, or die from poliovirus or non-poliovirus related causes \[[@r9]\].

As iVDPVs continue to diverge, accumulating numerous amino acid substitutions in receptor binding epitopes and neutralising antigenic epitopes, the probability for transmission appears to decrease \[[@r9],[@r11]\]. To date, there is only one documented case of transmission of iVDPV \[[@r12]\], but none for very highly diverged VDPVs \[[@r11]\]. This may be due in part to their need to adapt for persistence in a specific sub-region of the gut. The simultaneous presence of different lineages of highly diverged polioviruses in a PID patient without evidence of interaction (no recombination) \[[@r9],[@r13]\] and from environmental surveillance samples containing polioviruses presumably excreted from a different unidentified single individual \[[@r5]\] suggests replication of the different lineages in separate locations and supports specialisation which may come at the expense of transmissibility. However, early in the process of iVDPVs' adapting for persistence, the genome of the virus is most similar to the parent OPV strain and newly emerging cVDPVs and could presumably spread within the general population as cVDPVs can \[[@r9]\]. Moreover initial mutations tend to restore fitness to vaccine strains and reverse attenuation for neurovirulence \[[@r9],[@r11],[@r14]\] as in the current case we present.

Epidemiological implications
============================

During this eight-month interval, GAP III restrictions governing use of PV2 in non-essential laboratories came into force. GAP III provides clear instructions for containing PV2 and mitigating its transmission from laboratories \[[@r3]\]. However, no such global restrictions or general standard operating procedures exist for handling of persistent or prolonged infection of PIDs in a closed hospital setting where there may even be a higher risk of transmission through staff, family, or other close contacts to other PID patients or to the general population. The same four conditions that were of concern for transmission in poliovirus laboratories \[[@r15]\] occur in paediatric wards for immune deficient patients and raise concern for heightened risk of re-emergence of PV2 from this source during the critical transition time to a PV2-free world. Namely: (i) high concentrations of VDPV2, primarily in stools but possibly also respiratory samples are present; (ii) repeated exposure to high concentrations of poliovirus over long periods of time in a closed setting by attending medical, janitorial and laundry staff, equipment maintenance staff, family members especially those who stay overnight with their children, and specialised procedure medical teams; (iii) susceptibility of these primary contacts to infection and especially other naïve PID patients in the same ward who might be exposed through shared primary contacts and who lack an immune system capable of protection against infection and disease; and (iv) the general community protected from disease, but less so against infection.

Conclusions
===========

Re-emergence of VDPV2 from PIDs will be difficult to detect since infection of the immediate professional staff will be asymptomatic due to vaccination and most community infections are also likely to be asymptomatic when vaccine coverage is very high, such as in Israel \[[@r14],[@r16]\]. Two models of the sustained transmission of WPV type 1 (WPV1) in Israel in 2013--14 in the population that had \>95% coverage with three doses of inactivated poliovirus vaccine (IPV), predicted a delay of at least one year before any AFP cases might appear \[[@r17],[@r18]\] and in fact AFP surveillance failed to document the sustained asymptomatic transmission of WPV1 throughout this period of sustained transmission \[[@r14],[@r16]\].

It is critical in this transition period to identify and contain all PIDs infected with and excreting PV2. For the reasons above, we strongly recommend active paediatric PID stool surveillance at least of patients with a recent history of OPV vaccination even though a number of studies indicate that prolonged excretion among PIDs is rare \[[@r8],[@r11],[@r19]\]. The need to screen PIDs will decrease as the transition time from the tOPV to bOPV increases. There is also an urgent need for global instructions on how to care for these patients and how to monitor contacts.

Ethics statement
================

The Ethical Review Board of the Sheba Medical Center, Tel Hashomer, approved this study (SMC-3412--16) and exempted it from a requirement to obtain informed consent.

**Conflict of interest:** None declared.

**Authors' contribution:** MW, DS, LMS, EM conceived and designed the study; JA, LW, IS performed cell culture and molecular diagnosis; MW, DS, LMS, EM and VI contributed to analysis and interpretation of data; SH, TS collected and wrote the clinical case data; MW, DS, LMS, EM, VI drafted the article. EM and DS contributed equally. All authors approved the final version of the article.

[^1]: Correspondence: Merav Weil (<merav.weil@sheba.health.gov.il>)
